MTP-CA’s Response To COVID-19

March 20, 2020

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) takes seriously the potential impact of COVID-19 (novel coronavirus) on the ALS community. We are committed to ensuring a safe and reliable ongoing supply of RADICAVA® (edaravone). We are well prepared from a product availability perspective with ample supply to meet Canadian patient needs for access to treatment.

The MTP Patient Support™ Program has a fully operational team in place and is available to provide information and guidance for healthcare providers, patients and their caregivers regarding ordering, infusion access and site of care support. Anyone needing assistance should call MTP Patient Support at 1-833-211-6878.

MTP-CA has been in contact with our main distributors. They are fully operational and have contingency plans in place for the pandemic. Be assured that the COVID-19 virus outbreak has not impacted the established safety profile or quality of our product. In addition, the company is working closely with our production facilities as part of our commitment to doing all we can to ensure our global supply chain remains uninterrupted.

It’s important to reiterate that MTP-CA is made up of a deeply devoted team of caring and compassionate individuals. During this uncertain time, we want you to know that our Canadian field and headquarters colleagues remain working and available to help. We will continue to follow the situation closely and provide updates as needed.

Patients with medical questions should speak to their healthcare provider regarding their care and wellness during the pandemic. For additional medical questions, please call the MTP-CA medical information line at 1-888-212-2253.